Damian Clarke-Bruce

Damian Clarke-Bruce is a seasoned executive in the biotech and pharmaceutical industries, currently serving as the CEO and Managing Director of HaemaLogiX Ltd, where innovative immunotherapies for blood cancers are under development. Damian's broad expertise encompasses strategic roles, including a position on the Board of Directors at Adnovate Clinical and as an International Commercialization & Strategy Consultant for Bilby Therapeutics. Previous leadership roles include CEO of Race Oncology and Executive Director of Global Marketing at Pharming Group N.V., focusing on rare diseases. Damian's career includes significant contributions at Novartis, where leadership in the neuroscience sector spanned multiple roles, driving commercialization for therapies in Multiple Sclerosis, Parkinson's, and Alzheimers. Education credentials include executive programs at Harvard Business School and MIT Sloan, alongside degrees in rehabilitation counseling and sports science.